I'd also like to see the B-OM trial get some giddy-up in its step. A while back (quite a while now actually) I felt B-OM could become the first FDA-approved drug to emerge from the CTIX stable. That seems less likely now. I have great confidence that B-OM performs as advertised, therefore the slow pace of the current trial is frustrating.
Don't you find it kind of odd that the stock price is only 3.11 after a 20 for 1 reverse split? If you revert back that's like .17 cents. That in itself is a red flag. CTIX has a low stock price, but no where near the calibur of this company. A market cap of 11 million???? Red Flag, Red Flag.